Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical ...

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

Loss of p53 strongly drives the progression of disease from Barrett's to cancer. The team found that potentially cancerous cells that lost both CDKN2A and p53 were weakened and unable to compete ...

The TP53 gene is a gene that is mutated in many cancers. It is the most common gene mutation found in cancer cells. A tumor-suppressor gene, TP53 codes for a protein that inhibits the development and ...

The C-terminal 19 amino acids of wild type p53 suppress the p53 response at sublethal doses of radiation. In contrast to cancer cells, mutant p53 activities are not well defined in nonmalignant cells.

The heterozygous 172H/+ genotype has an expanded transcriptome compared to wild type p53. In contrast to cancer cells, mutant p53 activities are not well defined in nonmalignant cells. To examine this ...

The absence of p53 significantly accelerates the progression from Barrett's esophagus to cancer. So, the researchers discovered that cells losing both CDKN2A and p53 became weaker and less capable ...

While this discovery did not kill the cancer cells, it did slow the growth. The team went on to find that a protein called p53 was cancer’s “plan B.” “The p53, which is functionally ...

A common aromatic shrub that has served as traditional medicine for centuries could point the way toward innovative ...